Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. - Barron's
1. UBS downgraded Novo Nordisk to Neutral, cutting price target significantly. 2. Competition from cheap GLP-1 drug knockoffs is impacting expected earnings. 3. Novo revised its 2025 sales growth forecast down to 8%-14% from 13%-21%. 4. Trump's proposed Medicare reimbursement could potentially increase volumes. 5. Novo shares fell 20% after the guidance cut, showing over 60% losses.